Healing / recovery

TB-500

Also known as Thymosin Beta-4

Systemic healing and flexibility, the classic partner to BPC-157.

Emerging evidence

Overview

TB-500 is a synthetic fragment of Thymosin Beta-4, a protein found throughout the body that plays a key role in cell migration, tissue repair, and blood vessel formation. The fragment used in TB-500 retains the biological activity relevant to healing - specifically promoting cell movement into damaged tissue, supporting new blood vessel growth, and accelerating overall tissue repair. Where BPC-157 acts more locally and is often injected near an injury site, TB-500 tends to act more systemically - supporting healing throughout the body from a central injection site. The two are frequently combined for this reason: they address healing through complementary mechanisms and together cover both local and systemic repair. TB-500 is a strong match for people dealing with acute or chronic injuries, slower-than-expected post-training recovery, or conditions affecting tendons and connective tissue. It also has minor supporting roles in muscle recovery and hair growth. It is administered as a subcutaneous injection, 1 to 2 times per week. Dose range is 2 to 5 mg. The standard protocol involves a loading phase of 4 to 8 weeks followed by a taper - the loading phase provides higher-frequency dosing to establish tissue levels, which can then be maintained at lower frequency. TB-500 carries a theoretical caution regarding active cancer: its pro-growth and angiogenesis-supporting properties mean it is not recommended for people with a cancer history. It is a research compound, not FDA-approved. Evidence is at the emerging stage - animal and small human studies support its use, but large clinical trials have not been conducted. Exact dosing, loading phase structure, and cycle length are set with a licensed provider in the PepDepo network at consult.

At a glance

Route

SC injection

Dose

2-5 mg

Frequency

1-2x per week

Timing

Any time

Cycle

4-8 weeks loading, then taper

Combining

Stacks well with: BPC-157

Safety

Theoretical caution with active cancer.

Regulatory: Research compound.

Not appropriate if: cancer-history.

Questions

How does TB-500 differ from BPC-157?⌄

BPC-157 is often injected near the injury site for localized repair. TB-500 acts more systemically - it can be injected anywhere and supports repair throughout the body. The two complement each other well and are frequently used together.

How is it taken?⌄

Subcutaneous injection, 1 to 2 times per week. Dose range is 2 to 5 mg. Protocol begins with a loading phase of 4 to 8 weeks, then tapers.

What are the main uses?⌄

Healing and recovery is the primary application - injuries, tendons, connective tissue, slower post-training recovery. It also has minor supporting effects on muscle recovery and hair growth.

Who should not use TB-500?⌄

People with a history of cancer should not use TB-500. Like BPC-157, its tissue-growth and angiogenesis-promoting properties present a theoretical concern with prior or active cancer.

Is it FDA-approved?⌄

No. TB-500 is a research compound. Evidence supporting its use is emerging - mostly animal data and smaller human observations, not large clinical trials.

What is the loading phase for?⌄

The loading phase (higher-frequency dosing over the first 4 to 8 weeks) is intended to build up tissue levels faster so the repair process gets a stronger initial push. After loading, dosing frequency is reduced to a taper or maintenance schedule.

Related protocols

Repair Wolverine

Want a personalized protocol?

Exact dosing is set with a licensed provider in the PepDepo network. This page is education, not a prescription.

Book a consult

Education only, not medical advice. Peptides discussed are for informational purposes and many are not FDA-approved. Eligibility, prescribing, compounding, and dispensing are handled by appropriately licensed entities. Exact protocols and dosing are set with a licensed provider in the PepDepo network at consult. Content is pending clinical review.